ABSTRACT
A good starting point for total access is the data the drug companies have submitted to drug agencies. The drug industry’s arguments have been equally absurd and exploitative of patients. Although the European Medicines Agency's (EMA) primary aim is to protect the public, the EMA replied that the documents could not be released because it would undermine commercial interests. In November 2010, the EMA declared it would widen public access to documents, including trial reports and protocols. The drug was withdrawn in 1997, as it causes pulmonary hypertension and a serious form of fibrosis of the heart valves that also kills people. Slimming pills are poor drugs that are not liked by the patients. In drug trials, doctors have financial incentives for keeping patients on the drug, but in real life, the situation is very different.
